Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFRACT: Nintedanib plus docetaxel in second-line treatment for refractory non-squamous non-small cell lung cancer
2015-000475-27Phase 2Completed
- Sponsor
- CHU de Limoges
- Start
- Jul 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of nintedanib and docetaxel in non-small cell lung cancer (NSCLC), sponsored by CHU de Limoges. Primary endpoint: Median progression-free survival at 12 weeks. Started Jul 2015; status: completed.
02
Drugs
nintedanibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-000475-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000475-27.